Good morning :)
Switch to
Place Order

Sun Pharma Advanced Research Co Ltd

SPARC
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,760 cr, stock is ranked 444
Moderate RiskStock is 2.78x as volatile as Nifty
250.400.70% (+1.75)
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹6,760 cr, stock is ranked 444
Moderate RiskStock is 2.78x as volatile as Nifty

Key Metrics

PE RatioPE RatioPB RatioPB RatioDividend YieldDiv. Yield
-33.24216.47
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
35.924.360.88%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy). The Company operates through Pharmaceuticals Research & Development segment. Its programs include Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispersion (Taclantis), Salmeterol - Fluticasone Dry Powder Inhaler (DPI), SUN-K706, Brimonidine OD, Tizanidine ER, Minocycline Topical and SUN-597 Topical. Xelpros is a Benzalkonium Chloride (BAK)-free Latanoprost eye drops developed with its Swollen Micelle Microemulsion (SMM) technology. Elepsia XR is a once-a-day formulation of Levetiracetam, an antiepileptic agent. Baclofen GRS is a once-a-day formulation of Baclofen, a centrally acting, antispasmodic drug. Taclantis is a Cremophor and Albumin free formulation. Its DPI is a premetered, 60 doses, breath activated device to administer combination of Salmeterol and Fluticasone by inhalation.

Investor PresentationView older 

Oct 28, 2022

PDF
View Older Presentations

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Financial TrendFinancial statements 

2019202020212022+196.38+86.57+258.37+144.09-145.42-312.41-151.14-203.40
Revenue
Profit
Loss
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent EventsAll events 

Related Party Transaction 
Announced OnNov 22, 2022

Sun Pharma Advanced Research Company Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Sun Pharma Advanced Research Company Limited has informed the Exchange about related party transaction for the period ended September 2022 | Download

Press Release 
Announced OnNov 18, 2022

Sun Pharma Advanced Research Company Limited has informed the Exchange about press release dated 18-Nov-2022 titled Press Release: SEZABY TM (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures | Download

Sun Pharma Advanced Research Company Limited has informed the Exchange about press release dated 18-Nov-2022 titled Press Release: SEZABY TM (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures | Download

General updates 
Announced OnNov 15, 2022

Sun Pharma Advanced Research Company Limited has informed the Exchange about Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 | Download

Sun Pharma Advanced Research Company Limited has informed the Exchange about Submission of Certificate from Statutory Auditor in terms of Regulation 169(5) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 | Download

See all events